Vertex Pharmaceuticals’ Revenue by Product (2016-2022)

This statistics highlights Vertex Pharmaceuticals’ Revenue by product, split between Trikafta/Kaftrio, Symdeko/Symkevi, Orkambi, Kalydeco medicines, reported on a quarterly basis from Q1 2016 onwards.

Vertex pharmaceutical invests in scientific innovation to create transformative medicines for people with serious and life-threatening diseases. They market their products through personal interactions with physicians and allied health care professionals.  Their strategy is to understand and work upon different human diseases and the science of therapeutics to discover and develop new medicines.

Vertex Pharmaceuticals’ Revenue by Product category

(All figures are in billions, except percentage)

Vertex generates nearly all of its revenue from it’s Trikafta product.  Their total revenue increased from $1.52 billion in Q3 2020 to $1.9 billion in Q3 2021 marking a 29.16 % increase on a year-on-year basis.

Vertex pharmaceutical products are classified into the following categories:

Trikafta/Kaftri

It is a prescription medicine used for the treatment of cystic fibrosis in patients aged 6 years and older who have at least one copy of the F508del mutation in the cystic fibrosis.

Vertex revenue from Trikafta medicine amounted to $1.55 billion in Q3 2021 up by $5.96 from $0.59 billion in Q3 2020 on a year-on-year basis. It also grew by 24% compared to $1.25 billion earned in Q2 2021.. Trikafta/Kaftri contributed to 78.43% of the targeted total revenue in the latest quarter.

Symdeko/Symkevi

It is used for the treatment of cystic fibrosis (CF) in patients aged 6 years and older, having two copies of the F508del mutation, or at least one mutation in the CF gene.

Vertex revenue from Symdeko medicine amounted to $0.081 billion in Q3 2021 down by 46% from $0.15 billion in Q3 2020 on a year-on-year basis. It’s revenue also reduced by 37.69% compared to $0.13 billion earned in Q2 2021. Symdeko contributed 4.08% of the targeted total revenue.

Orkambi

This medicine is used for the treatment of cystic fibrosis (CF) in patients aged 2 years and older and who have two copies of the F508del mutation (F508del/F508del) in their CFTR gene.

Vertex revenue from Orkambi medicine amounted to $0.18 billion in Q3 2021 down by $0.04 billion as compared to Q3 2020 which had a revenue of $0.22 billion. Orkambi contributed to 9.32% of the targeted total revenue in the latest quarter.

Kalydeco

It is a prescription medicine which is used for the treatment of cystic fibrosis in patient’s aged 4 months and older who have at least one mutation in their CF gene.

Vertex revenue from Kalydeco medicine declined from $0.19 billion in Q3 2020 to $0.16 billion in Q3 2021 marking a decline by 12.5% on a year-on-year basis . The revenue also reduced by 11.11% in the latest quarter as compared to $0.18 billion earned in Q2 2021. Kalydeco contributed 8.17% of the targeted total revenue.

About the Company

Vertex Pharmaceutical Incorporation is a global biotechnology company that invests in scientific innovation to create transformative medicines for people having serious diseases with a focus on specialty markets. It was founded in 1989 in Cambridge, Mass by Joshua Boger,

Vertex is consistently recognized as one of the industry’s top places to work, including 11 consecutive years on Science magazine’s Top Employers list and the best place to work for LGBTQ Equality by the Human Rights Campaign.

Vertex was awarded as one of the 2020 honorees of the Civic 50, honored as one of the 50 most community-inclined companies in the United States.

Did you like Vertex pharmaceutical’s revenue by product Category statistic?

Access more such key performance indicator data points, on thousands of US stocks, with Business Quant.

You can get started here.